Vascarta Starts Phase I Trial of Innovative Curcumin Gel for Osteoarthritis Vascarta has initiated a Phase I clinical study of VAS101, a topical gel for treating osteoarthritis. The study aims to evaluate safety and efficacy over 28 days.

Vascarta Starts Phase I Trial of Innovative Curcumin Gel for Osteoarthritis #Australia #Osteoarthritis #Vascarta #Perth #VAS101

Reversing Aging Signs: VAS101's Groundbreaking Effects on Health A recent study in GeroScience highlights VAS101's promise as a curcumin transdermal formulation that reverses aging effects in mice.

Reversing Aging Signs: VAS101's Groundbreaking Effects on Health #USA #Vascarta #Curcumin #Summit #VAS101